Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIBELIUS: Steroid-Independent Belimumab Protocol for SLE Flares
jRCTs011190011Active, not recruiting
- Sponsor
- GSK
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, open-label trial of belimumab in systemic lupus erythematosus (SLE) (2 arms), sponsored by GSK. Primary endpoint: Primary safety endpoint: adverse events through 12 weeks. Started Nov 2020; status: active, not recruiting.
02
Drugs
belimumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on jRCTs011190011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs011190011.